<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[CureApp, Inc. 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=40494></link><description><![CDATA[CureApp, Inc. 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Mon, 06 Apr 2026 01:51:07 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><image><url><![CDATA[https://file.newswire.co.kr/data/upfile/company_img/2022/05/12_1026003021_20220506142329_9536652611.jpg]]></url></image><language>ko-KR</language><item><title><![CDATA[CureApp: Digital Therapeutic App for Hypertension Receives Insurance Coverage, Sales of the Service to Medical Institutions Across Japan Launch on September 1]]></title><link>https://www.newswire.co.kr/newsRead.php?no=954782</link><description><![CDATA[TOKYO--(Business Wire/Korea Newswire)--CureApp, Inc. (Head Office: Chuo-ku, Tokyo; CEO: Kohta Satake) announces the start of insurance coverage for its CureApp HT Hypertension Adjunctive Treatment App (hereafter, CureApp HT), a DTx[*1] solution treating hypertension, in Japan from September 1, 2022. Looking ahead, the app will be prescribed and provided to patients with hypertension ...]]></description><pubDate>Thu, 03 Nov 2022 13:50:00 +0900</pubDate></item><item><title><![CDATA[큐어앱의 고혈압 보조 치료 앱 ‘큐어앱 HT’, 일본서 9월 1일부터 의료보험 적용… 의료 기관에 판매]]></title><link>https://www.newswire.co.kr/newsRead.php?no=954783</link><description><![CDATA[도쿄--(Business Wire/뉴스와이어)--큐어앱(CureApp, Inc.)(본사: 도쿄 주오구, 최고경영자: 사타케 고타[Kohta Satake]이 고혈압 디지털 치료제(DTx[*1]) 큐어앱 HT 고혈압 보조 치료 앱(CureApp HT Hypertension Adjunctive Treatment App, 이하 큐어앱 HT)의 일본 내 의료보험 적용이 2022년 9월 1일부터 가능해졌다고 발표했다.   이에 따라 큐어앱 HT는 의료 기관에서 고혈압 환자에게 건강 보험 치료제로...]]></description><image><url><![CDATA[https://file.newswire.co.kr/data/datafile2/thumb/2022/11/31017998_20221103132406_6541254117.jpg]]></url></image><pubDate>Thu, 03 Nov 2022 13:50:00 +0900</pubDate></item><item><title><![CDATA[CureApp: World’s First Medical Device Regulatory Approval of Digital Therapeutic App for Hypertension]]></title><link>https://www.newswire.co.kr/newsRead.php?no=944060</link><description><![CDATA[TOKYO--(Business Wire/Korea Newswire)--CureApp, Inc. (Head Office: Chuo-ku, Tokyo; CEO: Kohta Satake) was notified by the Ministry of Health, Labour and Welfare on April 26, 2022 that the company had received the medical device regulatory approval of an digital therapeutic app for Hypertension. This marks the first time a standalone software app supporting doctors and patients has re...]]></description><pubDate>Fri, 06 May 2022 15:15:00 +0900</pubDate></item><item><title><![CDATA[큐어앱의 디지털 고혈압 치료 앱, 세계 최초로 의료 기기 규제 승인 획득]]></title><link>https://www.newswire.co.kr/newsRead.php?no=944061</link><description><![CDATA[도쿄--(Business Wire/뉴스와이어)--큐어앱(CureApp, Inc.)(본사: 도쿄 주오구, 최고경영자: 사타케 고타(Kohta Satake)의 디지털 고혈압 치료 앱이 4월 26일 일본 후생노동성(MHLW)로부터 의료 기기 규제 승인을 받았다.   큐어앱의 디지털 고혈압 치료 앱은 의사와 환자를 뒷받침하는 독립형 소프트웨어 앱 가운데 일본 최초로 의료 기기 규제 승인을 받았다. 큐어앱은 이 앱이 향후 전 세계에서 승인받을 수...]]></description><pubDate>Fri, 06 May 2022 15:15:00 +0900</pubDate></item></channel></rss>